Oncotarget · 2014 · 53 citations · 38 references
Life SciencesOncologyPharmacologyApoptosisMolecular OncologySignal TransductionApoptosis In CancerApoptosis ResistanceApoptotic SignalingCaspase ActivationCell DeathDeath ReceptorsAnti-apoptotic AgentsAnti-apoptotic ProteinsAnticancer ActivityApoptosis Signaling PathwaysApoptotic Signaling In CancerCell Death SensitizationExtracellular Signal-regulated Kinase PathwayTrail-mediated Apoptosis
// Eun Ah Shin 1,* , Eun Jung Sohn 1,* , Gunho Won 1 , Jeong-Un Choi 1 , Myongsuk Jeong 1 , Bonglee Kim 1 , Min-Jeong Kim 1 and Sung-Hoon Kim 1 1 Cancer Preventive Material Development Research Center, College of Oriental Medicine, Kyung Hee University, Seoul, South Korea * These authors equally contributed to this work Correspondence: Sung-Hoon Kim, email: // Keywords : TRAIL sensitizer, tanshinone I, apoptosis, DR5, miR135a, prostate cancer Received : April 12, 2014 Accepted : June 29, 2014 Published : June 30, 2014 Abstract Though tumor necrosis factor related apoptosis inducing ligand (TRAIL) has been used as a potent anticancer agent, TRAIL resistance is a hot-issue in cancer therapy. We investigated the antitumor mechanism of Tanshinone I to sensitize prostate cancer cells to TRAIL. Comibination of Tanshinone I and TRAIL exerted synergistic cytotoxicity, increased cleaved PARP, sub G1 population, the number of TUNELpositive cells, activated caspase 8, 9 and ROS production in PC-3 and DU145 cells. Of note, combination of Tanshinone I and TRAIL enhanced the protein expression of death receptor 5 (DR5) and attenuated anti-apoptotic proteins. RT-PCR and RT-qPCR analyses confirmed that co-treatment of Tanshinone I and TRAIL up-regulated DR5 and microRNA 135a-3p at mRNA level or activity of DR5 promoter and attenuated phosphorylation of extracellular signal regulated kinases in PC-3. Conversely, the silencing of DR5 blocked the increased cytotoxicity, sub G1 population and PARP cleavages induced by co-treatment of Tanshinone I and TRAIL. Interestingly, miR135a-3p mimic enhanced DR5 at mRNA, increased PARP cleavage, Bax and the number of TUNEL positive cells in Tanshinone I and TRAIL cotreated PC-3. Overall, our findings suggest that Tanshinone I enhances TRAIL mediated apoptosis via upregulation of miR135a-3p mediated DR5 in prostate cancer cells as a potent TRAIL sensitizer.
38
Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2012 · 10.7K citations · Full text
Ahmedin Jemal, Thomas S. Murray, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2005 · 5.5K citations · Full text
The Receptor for the Cytotoxic Ligand TRAIL
Guohua Pan, Karen O’Rourke, Arul M. Chinnaiyan et al. · Science · 1997 · 1.8K citations
TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL
Henning Walczak · The EMBO Journal · 1997 · 1.1K citations · Full text